| pubmed-article:9402329 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9402329 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:9402329 | lifeskim:mentions | umls-concept:C0011061 | lld:lifeskim |
| pubmed-article:9402329 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:9402329 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:9402329 | pubmed:dateCreated | 1998-1-29 | lld:pubmed |
| pubmed-article:9402329 | pubmed:abstractText | Cytarabine is intracellularly activated and correlations have been established between the pharmacokinetic behaviour of active metabolites and their antileukemic effect. Recently, a good response to high-dose treatment of leukemias has additionally been attributed to a so-called low deamination phenotype of cytarabine inactivation. Consequently, these findings would support plasma level monitoring of cytarabine and its metabolite uracil arabinoside in high-dose cytarabine regimens. This pharmacokinetic study presents data attempting to reevaluate these observations. Thirty-seven patients were treated by 3-h high-dose cytarabine infusions (9 patients 1000 mg/m2, 28 patients 3000 mg/m2) as part of their treatment for acute leukemia. Serial blood samples during and post infusion were analysed for cytarabine (araC) and its deamination product uracil arabinoside (araU) using HPLC with UV-detection. Considerable interindividual variation was observed in end-infusion plasma concentrations of araC (1000 mg/m2: 2.1-fold, 3000 mg/m2: 5.5-fold) and araU (1000 mg/m2: 2.7-fold, 3000 mg/m2: 2.9-fold). The median ratio of end infusion concentrations araU/araC (on a molar basis) was 5.6 (S.D. 3.0), extreme ratio values were 2 and 14. No differences of the araU/araC ratio were found between the two dosages used. Minimum plasma araC concentrations at the end of infusion were 10.5 micromol/l and 22.0 micromol/l at a dose of 1000 and 3000 mg/m2, respectively. In our European study population a "fast" deamination phenotype of cytarabine (araU/araC ratio > 14) was not be observed. | lld:pubmed |
| pubmed-article:9402329 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9402329 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9402329 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9402329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9402329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9402329 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9402329 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9402329 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9402329 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:SchneiderWW | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:BurnNN | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:ArningMM | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:HeyllAA | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:VolmerMM | lld:pubmed |
| pubmed-article:9402329 | pubmed:author | pubmed-author:FartashKK | lld:pubmed |
| pubmed-article:9402329 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9402329 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:9402329 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9402329 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9402329 | pubmed:pagination | 321-7 | lld:pubmed |
| pubmed-article:9402329 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:meshHeading | pubmed-meshheading:9402329-... | lld:pubmed |
| pubmed-article:9402329 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9402329 | pubmed:articleTitle | Pharmacokinetics of high-dose cytarabine and its deamination product--a reappraisal. | lld:pubmed |
| pubmed-article:9402329 | pubmed:affiliation | Clinic of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany. | lld:pubmed |
| pubmed-article:9402329 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9402329 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9402329 | lld:pubmed |
